Exploring Reasons For Poor Adherence To A Trust?s Warfarin Initiation Protocol | 13275
Clinical Pharmacology & Biopharmaceutics
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Warfarin is the most commonly prescribed oral anticoagulant in the UK, demonstrating effectiveness in preventing and
managing a range of thrombotic conditions. However due to factors including unpredictable pharmacokinetics, numerous
drug interactions and a narrow therapeutic range, reaching and maintaining therapeutic anticoagulation can be challenging.
The risks of over-anticoagulation and major bleeding are highest in the first four weeks of warfarin therapy. To reduce the risk
of bleeding related to warfarin initiation in one large UK-based Trust a warfarin initiation protocol was introduced. However,
previous Trust-wide audits revealed poor adherence to the protocol. The aim of this study was to identify reasons for poor
adherence to the protocol. Thirteen junior doctors across the Trust were interviewed using a semi-structured tool. In addition, a
related questionnaire was designed and distributed to junior doctors at training sessions to capture a wider sample. Key findings of
the study suggested that participants were aware of the protocol; with 85% of 20 surveyed participants and 92% of 13 interviewees
indicating awareness. However a number of potential barriers to protocol adherence were identified. Barriers included protocol
inaccessibility; concern of the safety of the protocol?s fixed dose regimen without INR monitoring for the first four days of therapy;
discrepancy between the Trust?s ?modest? initiation protocol and the more aggressive warfarin initiation regimens generally
favoured by participants? seniors. The study highlighted the need to address concerns about the safety of the protocol, increase
awareness of the Trust protocol to all levels of prescriber and improve protocol accessibility.
Frances Akinwunmi, first started working in anticoagulation in 2002 when she commenced a Ph.D. which explored the redesign of anticoagulation
services in different care settings. Over the years, Frances has delivered a variety of anticoagulation services in secondary and primary care. As
part of her current role she provides leadership through promoting clinical governance as it pertains to anticoagulation. Frances is a member of the
UKCPA Haemostasis Anticoagulation and Thrombosis committee and a board member of the multidisciplinary Anticoagulation in Practice Society,
contributing to the educational and conference activities of both.
Aside from anticoagulation, Frances has an interest in medicines adherence.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals